Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Regeneron Pharmaceuticals just hit a new 52-week low after UBS dropped its price target and slapped on a neutral rating.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

For more comprehensive information about current price movements while Regeneron shares crash, please visit CDS.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ), een biotechnologiebedrijf met een marktkapitalisatie van $ 52,62 mld. en een indrukwekkende "UITSTEKENDE" financiële gezondheidsscore volgens Investing ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Investing.com -- De aandelen van Maia Biotechnology Inc (NYSE American:MAIA) stegen vandaag met 3,4% nadat het bedrijf bemoedigende overlevingsdata rapporteerde uit zijn cruciale THIO-101 Fase 2 klini ...

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

US biotech Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced a strategic in-licensing agreement with China’s ...

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...